170.147
Bearbeitungen
Josef Thaler: Unterschied zwischen den Versionen
Zur Navigation springen
Zur Suche springen
K
→Publikationen (Auswahl)
K (→Einleitung) |
|||
| Zeile 2: | Zeile 2: | ||
== Publikationen (Auswahl)== | == Publikationen (Auswahl)== | ||
* mit Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH, Siena S.: Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.[[Journal of Clinical Oncology]]. 2008 Nov 20 18.37 | * mit Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH, Siena S.: Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.[[w:Journal of Clinical Oncology|Journal of Clinical Oncology]]. 2008 Nov 20 18.37 | ||
* mit Ludwig H, Adam Z, Hajek R, [[Richard Greil|Greil R]], Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N.: Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. Journal of clinical oncology. 2010 Oct 20 | * mit Ludwig H, Adam Z, Hajek R, [[w:Richard Greil|Greil R]], Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N.: Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. Journal of clinical oncology. 2010 Oct 20 | ||
* mit Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, [[Christoph Zielinski|Zielinski C]], Pabinger I.: Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011 May 20 | * mit Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, [[w:Christoph Zielinski|Zielinski C]], Pabinger I.: Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011 May 20 | ||
* mit Ahlbrecht J, Dickmann B, Ay C, Dunkler D, Schmidinger M, Quehenberger P, Haitel A, Zielinski C, Pabinger I.: Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study.J Clin Oncol. 2012 Sep 24 | * mit Ahlbrecht J, Dickmann B, Ay C, Dunkler D, Schmidinger M, Quehenberger P, Haitel A, Zielinski C, Pabinger I.: Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study.J Clin Oncol. 2012 Sep 24 | ||
* mit Grand FH, Burgstaller S, Kühr T, Baxter EJ, Webersinke G, Chase AJ, Cross NC.: p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res. 1900 Jan 1 | * mit Grand FH, Burgstaller S, Kühr T, Baxter EJ, Webersinke G, Chase AJ, Cross NC.: p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res. 1900 Jan 1 | ||
* mit Bechter OE, Eisterer W, Pall G, Hilbe W, Kühr T: Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. [[Cancer research]]. 1998 Nov 1 | * mit Bechter OE, Eisterer W, Pall G, Hilbe W, Kühr T: Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. [[w:Cancer research|Cancer research]]. 1998 Nov 1 | ||
* mit Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J.: Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. [[Annals of Oncology]]. 2011 Feb 1 | * mit Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J.: Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. [[w:Annals of Oncology|Annals of Oncology]]. 2011 Feb 1 | ||
== Ehrenämter (Auswahl)== | == Ehrenämter (Auswahl)== | ||